2 protocols meet the specified criteria
- OCR13631
Molecular Analysis for Therapy Choice (MATCH)
- OCR24642
An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy